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Abstracts / Osteoarthritis and Cartilage 20 (2012) S1–S9S2detailed chemotyping of cells under duress and can provide critical
insight in the activated pathways related to the progression of the
disease. Imaging mass spectrometry is ideally suited for this task as it
allows the generation of high resolution molecular images of a wide
variety of biological compounds from complex surfaces without the
need for chemical labels or antibodies. High ﬁdelity molecular ion
images can be generated using modern desorption and ionization
techniques combined with high end mass spectrometric systems. The
distribution of several hundreds of peptides and proteins on the surface
of histological tissue sections can be determined in a single imaging MS
experiment. This enables molecular pathway analysis and the role of
the different molecular signals and their behavior under a drastically
changing chemical or biological environment in these pathways.
The complexity of these pathways in diseases prohibits the detailed
chemical characterization by a single technique. We have developed an
approach that combines a number of innovative mass spectrometric
imaging approaches with bright ﬁeld imaging, magnetic resonance
imaging and targeted IHC images to reﬁne our understanding of oste-
oarthritis progression in human cartilage samples. In addition we have
integrated state-of-the-art quantitative proteomics and metabolomic
studies of selected tissues in our molecular imaging workﬂow. The
common histological tools typically only provide generic morphological
information unless immunohistochemistry is used to determine the
distribution one speciﬁc known protein. Imaging mass spectrometry
has evolved to bring these two disciplines, mass spectrometry and
histology. This approach, sometimes referred to as molecular histology,
can take great beneﬁt from the use of high resolution mass spectrom-
etry, gas-phase ion mobility separation and smart surface preparation
protocols. In an OA study we have created maps of peptide distribution
at 150 um of pixel size in control and OA human cartilage. We have
identiﬁed and localized proteins such as biglycan (PGS1), prolargin
(PRELP), decorin (PGS2) and aggrecan core protein (PGCA). Protein
markers speciﬁc to the OA pathology have been additionally imaged.
Cartilage oligomeric matrix protein (COMP) and ﬁbronectin (FINC)
peptides were exclusively found in the OA samples. Their distribution
displayed a stronger intensity in the deep compared to the superﬁcial
area. Combined they provide new molecular visualization tools for
biomedical researchers. These innovative developments towards high
resolution imaging mass spectrometry can reveal new tissue details
that remain hidden with conventional molecular imaging approaches.
In this contribution we will discuss applications of new chemical
microscopes in biomedical tissue analysis. This lecture will discuss how
imaging MS can elucidate the way in which local environments can
inﬂuence signaling pathways in diseases.
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IS IT TIME TO REVISIT THE SYMPTOMATIC OUTCOME VARIABLES TO
ASSESS OA TREATMENTS?
M. Dougados. René descartes Univ., Paris, France
1. The current conventional domains evaluating the symptoms of
patients suffering from osteoarthritis are mainly the ones of pain and
functional impairment. Some studies are incorporating also a patient/
physician global assessment. Such domains have been proposed by
physicians. Based on the experience of other rheumatic conditions (e.g.
rheumatoid arthritis) one could consider as relevant to revisit these
domains by asking the patients. Such patient's perspective might result
in different selection of domains.
2. Treatments in OA can be categorized in 2 mains categories: (a) the
ones aimed at improving the current patient's condition and (b) the one
aimed at preventing a subsequent poor condition.
The methodology used to assess drugs aimed at improving the patient's
condition is very well established despite the fact that some aspects
could be further improved such as (a) the phenotype of the recruited
patients (e.g. diagnostic criteria, severity scoring system, co-existence of
inﬂammation), (b) the study design and, in particular, the so-called
“withdrawal design”, “discontinuation trial”.
The methodology to assess the symptoms during OA trials evaluating
drugs aimed at preventing a subsequent poor condition is usually
similar than the one used to assess treatments aimed at improving the
patient's condition. This approach was and is responsible of some
disappointing results. It seems reasonable that the outcome variables
reﬂect the main objective of these treatment (e.g. prevention). There-
fore, the studies evaluating such potential treatments should use as an
outcome variable a poor condition or a not acceptable condition. Thiswas the rationale of the OARSI-OMERACT initiative which is now
proposing an outcome variable deﬁning such poor condition or not
acceptable condition. Such composite index is a combination of non
acceptable symptoms (pain and function) states observed during
a certain period of time (at least 2 consecutive visits 3 months a part)
together with a structural progression deﬁned by a worsening in the
joint space narrowing of at least 0.5 mm.
Prospective studies have to be further conducted in order to evaluate
the relevance and the feasibility of this proposal.
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CARTILAGE AND JOINT DEVELOPMENT
V. Lefebvre. Cleveland Clinic, Cleveland, OH
Osteoarthritis clinically manifests itself by joint pain, deformation, and
reduced mobility, and it is biologically characterized by progressive
and irreversible degeneration of articular cartilage. The disease has
major negative impact on affected individuals and the society as
a whole both because of its high prevalence and because of current
lack of cures. Today's treatments indeed focus on pain relief and
arthroplasty, but they are not curative, because efﬁcient procedures to
block cartilage degeneration and restore normal tissue structure and
function remain nonexistent. A key factor in the development of
osteoarthritis, which is also a major obstacle in the design of curative
treatments, is that adult articular chondrocytes virtually lack intrinsic
mechanisms to properly repair tissue damage. We therefore believe
that new strategies to cure osteoarthritis should be devised based on
recapitulating the mechanisms that lead chondrocytes to form artic-
ular cartilage during development and help the cells maintain tissue
homeostasis in early adult life. In this keynote lecture, we will review
current understanding of these mechanisms, and will focus on recent
discoveries and lingering gaps in knowledge. In particular, we will
present new data from our laboratory on the roles of Sox9 in chon-
drogenesis. Sox9 was previously demonstrated to be a pivotal tran-
scription factor in early chondrogenesis in the embryo, since it
commits multipotent mesenchymal cells to the chondrocyte lineage
and directly activates the early chondrocyte differentiation program.
While it was originally proposed that Sox9 might inhibit chondrocyte
proliferation and hypertrophic maturation in the cartilage growth
plate, we have found, by combining conditional knockout strategies in
the mouse with advanced molecular approaches, that Sox9 is actually
necessary for growth plate development. Sox9 sustains chondrocyte
proliferation, at least in part by preventing prehypertrophic differen-
tiation. It is then required to maintain the lineage fate of chondrocytes
by blocking differentiation of prehypertrophic cells into osteoblasts,
and it cooperates with the transcription factor Mef2c to directly
activate the hypertrophic chondrocyte program. Sox9 is thus a key
transcription factor throughout the differentiation program of fetal
chondrocytes. These ﬁndings suggest that Sox9 could have similar
roles in articular cartilage throughout life, and we will show prelim-
inary data from our laboratory that supports this hypothesis. We thus
propose that osteoarthritic conditions could lead to articular cartilage
degeneration as a result of Sox9 gene downregulation or as a result of
a switch in Sox9 protein activity, from promoting an articular
phenotype to activating a growth plate chondrocyte fate. Thus, while
curative strategies for osteoarthritis should promote expression of the
Sox9 gene, as a mandatory chondrogenic driver, they should also
ensure that the activity of the encoded transcription factor is properly
directed towards driving an active and healthy articular chondrocyte
phenotype.
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UPDATE ON PHARMACOLOGIC MANAGEMENT OF OSTEOARTHRITIS
T.J. Schnitzer. Northwestern Univ. Feinberg Sch. of Med., Chicago, IL
Purpose: Provide an overview of new approaches to the management
of osteoarthritis (OA).
Methods: Review of the recent literature.
Results: A number of studies have recently concluded that have
addressed both symptom and disease modiﬁcation in OA. These studies
are expanding our understanding of the mechanisms associated with
pain generation and perception in OA as well as providing insight into
the importance of pathways of cartilage metabolic homeostasis,
respectively. Reduction of peripheral nerve input, attained by means of
monoclonal inhibition of nerve growth factor (NGF), a neurotrophin
